Authors | Journal | Major tumor cells used | Major mouse models used | Proposed source(s) of PD-L1 contributed to tumor evasion |
---|---|---|---|---|
Noguchi et al. [3] | Cancer Immunology Research | MCA-induced sarcoma T3 and T9; T3ΔPDL1 clones; T9-PD-L1ovr clone; T9-PD-L1phy clone; | 129S6 WT and Rag2−/− mice | Both tumors and host immune cells (particularly tumor associated macrophages) |
Lau et al. [4] | Nature Communications | Colon tumor MC38 and CT26; PD-L1-KO/inducible MC38/CT26 clones; | BALB/c; C57BL/6; Rag2−/−; PD-L1−/− mice | Disparate cellular sources, including tumor cells, myeloid or other immune cells |
Kleinovink et al. [5] | OncoImmunology | MC38 and CT26; PD-L1-KO MC38/CT26 clones | C57BL/6; BALB/c mice | Both malignant cells and immune cells |
Juneja et al. [6] | The Journal of Experimental Medicine | MC38; melanoma B16.F10; BRAF.PTEN; PD-L1-KO MC38/BRAF.PTEN clones | C57BL/6; PD-1−/−; PD-L1−/−; PD-L1−/−PD-L2−/− mice | Context-dependent; For MC38 model, PD-L1 on tumors; For BRAF.PTEN and B16.F10 + Gvax models, PD-L1 on non-tumor cells |
Tang et al. [7] | The Journal of Clinical Investigation | MC38, B lymphoma A20; T lymphoma E.G7; PD-L1-KO MC38/A20 clones | C57BL/6; BALB/c; Rag1−/−; CD11b-DTR; NSG; PD-L1−/− mice | The contribution of PD-L1 on tumor cells is largely dispensable; PD-L1 on host myeloid cells is essential |
Lin et al. [8] | The Journal of Clinical Investigation | MC38; B16-F10; lung cancer LLC; ovarian cancer ID8; PD-L1-KO/over-expression MC38/ID8/B16-F10 clones; | C57BL/6; NSG; Rag1−/−; PD-L1−/−; PD-1−/− mice | PD-L1 on tumor cells does not contribute to PD-L1 blockade efficacy; PD-L1 on host DCs and macrophages predicts clinical efficacy of PD-L1/PD-1 blockade |